Treatment Costs of Basal Insulin Regimens for Type 2 Diabetes Mellitus in France.

ABSTRACT:

Objective

Our objectives were to describe the basal insulin treatment regimens most widely used in a real-world setting in France and to estimate the associated treatment costs in people with type 2 diabetes mellitus (T2DM).

Methods

A cross-sectional observational study was conducted (November 2017-February 2018) among adult patients with T2DM requiring basal insulin therapy for their own use in a representative sample of pharmacies. Costs were compared between patients treated with three recently marketed insulins (glargine 300 U/ml [Gla-300], biosimilar glargine 100 U/ml [Gla-100] and a fixed-ratio combination of insulin degludec and liraglutide) and those treated with three established basal or intermediate insulins: branded glargine 100 U/ml, insulin detemir and neutral

SUBMITTER: Detournay B 

PROVIDER: S-EPMC8160062 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature